{"success":true,"data":{"pressRelease":{"id":"65008","rtpr_id":"nGNX2dy3y4","ticker":"MBOT","exchange":"NASDAQ","all_tickers":["MBOT"],"title":"Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations","author":"Globe Newswire","published_at":"2026-06-16T12:30:00.586Z","article_body":"HINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc.\n(Nasdaq: MBOT), developer and distributor of the innovative LIBERTY(®)\nEndovascular Robotic System, has entered into an agreement with Lovell(®)\nGovernment Services to serve federal healthcare systems, such as those\nadministered by the Veterans Health Administration (VHA), a division of the\nU.S. Department of Veteran Affairs, the Military Health System (MHS), which is\nrun by the U.S. Department of Defense, and the U.S. Indian Health Service\n(IHS). Lovell Government Services will become Company’s Service-Disabled\nVeteran-Owned Small Business (SDVOSB) vendor to serve these customers through\nfederal contracting systems.\n\nLovell Government Services has been a SDVOSB vendor since 2013 with a track\nrecord of introducing suppliers to the government market. Lovell is a\nfour-time Inc. 5000 honoree. Microbot Medical’s LIBERTY System will be added\nto Lovell’s Federal Supply Schedule (FSS) contract, with activation expected\nduring the third quarter of 2026. The LIBERTY System will also be accessible\nthrough additional federal procurement platforms, including GSA Advantage, the\nDefense Logistics Agency’s Electronic Catalog (ECAT), and the Department of\nDefense’s Distribution and Pricing Agreement (DAPA). Listing products with\nLovell is expected to streamline the sales process while helping government\nagencies meet their SDVOSB procurement goals. Lovell serves thousands of\ngovernment care sites nationwide, including 170 medical centers and numerous\noutpatient clinics, averaging over 200 peripheral endovascular cases annually,\nper site.\n\n“We are proud to partner with Microbot Medical to help expand access to\ninnovative healthcare technologies for our nation's veterans, active-duty\nservice members, and Native American communities,\" said Chris Lovell, Major,\nUSMC (Ret.), CEO of Lovell Government Services. \"The LIBERTY(®) Endovascular\nRobotic System represents a significant advancement in minimally invasive\nvascular care, and we look forward to supporting its availability across\nfederal healthcare systems. Our mission is to connect government providers\nwith best-in-class solutions that improve patient outcomes while simplifying\nthe procurement process, and this partnership reflects that commitment.\"\n\n“As someone who has represented the U.S. in two Olympics, it is an honor to\njoin with Lovell to ensure those who have served in the military along with\ntheir physicians have access to advanced medical technologies that address\ntheir needs,” commented Christina Bailey, Vice President, U.S. Sales.\n“Building on our continued commercial momentum, we believe this partnership\nwill expand awareness and adoption of our technology across Lovell’s\nextensive network. Contracted access is a key component of our commercial\nstrategy, providing customers with a streamlined procurement pathway and\nconfidence in product availability. As interest in our technology continues to\ngrow, we believe now is the right time to start this relationship and its\npotential for broader adoption.”\n\nAbout Microbot Medical\n\nMicrobot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device\ncompany focused on transforming endovascular procedures through advanced\nrobotic technology. Microbot’s LIBERTY(®) Endovascular Robotic System is\nthe first single-use, remotely operated robotic solution designed for\nprecision, efficiency and safety. Backed by a strong intellectual property\nportfolio and a commitment to innovation, Microbot is driving the future of\nendovascular care.\n\nLearn more at www.microbotmedical.com and connect on LinkedIn\n(https://www.globenewswire.com/Tracker?data=_vVMo7QU10Wd6wSO-BDwsBtDiCi1X-JfKcjFHAha9PdspXXlfAkpvEIn0FDM19UTl8nAVsZHuYL74hdx5cK0Y0t7HpHYm7BDslh92MCf9xu4MNhqch5lORdaJyGzbdLT)\nand X\n(https://www.globenewswire.com/Tracker?data=NJYcTY5ZQvxfDivQMB0sWCD13vRsfybXLpLDzTAdT19KVDY6-EKO1l49o8fHKkC9bwa-HVWe6xAKP6cP-qSRHg==).\n\nSafe Harbor\n\nStatements to future financial and/or operating results, future adoption of\nproducts, future growth in research, technology, clinical development,\ncommercialization and potential opportunities for Microbot Medical Inc. and\nits subsidiaries, along with other statements about the future expectations,\nbeliefs, goals, plans, or prospects expressed by management, constitute\nforward-looking statements within the meaning of the Private Securities\nLitigation Reform Act of 1995 and the Federal securities laws. Any statements\nthat are not historical fact (including, but not limited to statements that\ncontain words such as “contemplates,” “continues,” “could,”\n“forecasts,” “intends,” “may,” “might,” “possible,”\n“potential,” “predicts,” “projects,” “should,” “would,”\n“will,” “believes,” “plans,” “anticipates,” “expects,”\n“estimates” and similar expressions) should also be considered to be\nforward-looking statements, but the absence of these words does not mean that\na statement is not forward-looking. Forward-looking statements involve risks\nand uncertainties, including, without limitation, market conditions, risks\ninherent in the commercialization of the LIBERTY(®) Endovascular Robotic\nSystem, and in the development of future versions of or applications for the\nsystem, uncertainty in the results of regulatory pathways and regulatory\napprovals, uncertainty resulting from political, social and geopolitical\nconditions, particularly any changes in personnel or processes or procedures\nat the FDA and announcements of tariffs on imports into the U.S., disruptions\nresulting from new and ongoing hostilities between Israel and the\nPalestinians, Iran and other neighboring countries, and maintenance of\nintellectual property rights. Additional information on risks facing Microbot\nMedical(®) can be found under the heading “Risk Factors” in Microbot\nMedical’s periodic reports filed with the Securities and Exchange Commission\n(SEC), which are available on the SEC’s web site at www.sec.gov. Microbot\nMedical(®) disclaims any intent or obligation to update these forward-looking\nstatements, except as required by law.\n\nContacts: \nIR@microbotmedical.com\nMedia@microbotmedical.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/346df7fb-c134-40c2-970a-39bcbaf974cd)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2dy3y4","title":"Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations","author":"Globe Newswire","ticker":"MBOT","created":"2026-06-16T12:30:00.586Z","tickers":["MBOT"],"exchange":"NASDAQ","article_body":"HINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc.\n(Nasdaq: MBOT), developer and distributor of the innovative LIBERTY(®)\nEndovascular Robotic System, has entered into an agreement with Lovell(®)\nGovernment Services to serve federal healthcare systems, such as those\nadministered by the Veterans Health Administration (VHA), a division of the\nU.S. Department of Veteran Affairs, the Military Health System (MHS), which is\nrun by the U.S. Department of Defense, and the U.S. Indian Health Service\n(IHS). Lovell Government Services will become Company’s Service-Disabled\nVeteran-Owned Small Business (SDVOSB) vendor to serve these customers through\nfederal contracting systems.\n\nLovell Government Services has been a SDVOSB vendor since 2013 with a track\nrecord of introducing suppliers to the government market. Lovell is a\nfour-time Inc. 5000 honoree. Microbot Medical’s LIBERTY System will be added\nto Lovell’s Federal Supply Schedule (FSS) contract, with activation expected\nduring the third quarter of 2026. The LIBERTY System will also be accessible\nthrough additional federal procurement platforms, including GSA Advantage, the\nDefense Logistics Agency’s Electronic Catalog (ECAT), and the Department of\nDefense’s Distribution and Pricing Agreement (DAPA). Listing products with\nLovell is expected to streamline the sales process while helping government\nagencies meet their SDVOSB procurement goals. Lovell serves thousands of\ngovernment care sites nationwide, including 170 medical centers and numerous\noutpatient clinics, averaging over 200 peripheral endovascular cases annually,\nper site.\n\n“We are proud to partner with Microbot Medical to help expand access to\ninnovative healthcare technologies for our nation's veterans, active-duty\nservice members, and Native American communities,\" said Chris Lovell, Major,\nUSMC (Ret.), CEO of Lovell Government Services. \"The LIBERTY(®) Endovascular\nRobotic System represents a significant advancement in minimally invasive\nvascular care, and we look forward to supporting its availability across\nfederal healthcare systems. Our mission is to connect government providers\nwith best-in-class solutions that improve patient outcomes while simplifying\nthe procurement process, and this partnership reflects that commitment.\"\n\n“As someone who has represented the U.S. in two Olympics, it is an honor to\njoin with Lovell to ensure those who have served in the military along with\ntheir physicians have access to advanced medical technologies that address\ntheir needs,” commented Christina Bailey, Vice President, U.S. Sales.\n“Building on our continued commercial momentum, we believe this partnership\nwill expand awareness and adoption of our technology across Lovell’s\nextensive network. Contracted access is a key component of our commercial\nstrategy, providing customers with a streamlined procurement pathway and\nconfidence in product availability. As interest in our technology continues to\ngrow, we believe now is the right time to start this relationship and its\npotential for broader adoption.”\n\nAbout Microbot Medical\n\nMicrobot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device\ncompany focused on transforming endovascular procedures through advanced\nrobotic technology. Microbot’s LIBERTY(®) Endovascular Robotic System is\nthe first single-use, remotely operated robotic solution designed for\nprecision, efficiency and safety. Backed by a strong intellectual property\nportfolio and a commitment to innovation, Microbot is driving the future of\nendovascular care.\n\nLearn more at www.microbotmedical.com and connect on LinkedIn\n(https://www.globenewswire.com/Tracker?data=_vVMo7QU10Wd6wSO-BDwsBtDiCi1X-JfKcjFHAha9PdspXXlfAkpvEIn0FDM19UTl8nAVsZHuYL74hdx5cK0Y0t7HpHYm7BDslh92MCf9xu4MNhqch5lORdaJyGzbdLT)\nand X\n(https://www.globenewswire.com/Tracker?data=NJYcTY5ZQvxfDivQMB0sWCD13vRsfybXLpLDzTAdT19KVDY6-EKO1l49o8fHKkC9bwa-HVWe6xAKP6cP-qSRHg==).\n\nSafe Harbor\n\nStatements to future financial and/or operating results, future adoption of\nproducts, future growth in research, technology, clinical development,\ncommercialization and potential opportunities for Microbot Medical Inc. and\nits subsidiaries, along with other statements about the future expectations,\nbeliefs, goals, plans, or prospects expressed by management, constitute\nforward-looking statements within the meaning of the Private Securities\nLitigation Reform Act of 1995 and the Federal securities laws. Any statements\nthat are not historical fact (including, but not limited to statements that\ncontain words such as “contemplates,” “continues,” “could,”\n“forecasts,” “intends,” “may,” “might,” “possible,”\n“potential,” “predicts,” “projects,” “should,” “would,”\n“will,” “believes,” “plans,” “anticipates,” “expects,”\n“estimates” and similar expressions) should also be considered to be\nforward-looking statements, but the absence of these words does not mean that\na statement is not forward-looking. Forward-looking statements involve risks\nand uncertainties, including, without limitation, market conditions, risks\ninherent in the commercialization of the LIBERTY(®) Endovascular Robotic\nSystem, and in the development of future versions of or applications for the\nsystem, uncertainty in the results of regulatory pathways and regulatory\napprovals, uncertainty resulting from political, social and geopolitical\nconditions, particularly any changes in personnel or processes or procedures\nat the FDA and announcements of tariffs on imports into the U.S., disruptions\nresulting from new and ongoing hostilities between Israel and the\nPalestinians, Iran and other neighboring countries, and maintenance of\nintellectual property rights. Additional information on risks facing Microbot\nMedical(®) can be found under the heading “Risk Factors” in Microbot\nMedical’s periodic reports filed with the Securities and Exchange Commission\n(SEC), which are available on the SEC’s web site at www.sec.gov. Microbot\nMedical(®) disclaims any intent or obligation to update these forward-looking\nstatements, except as required by law.\n\nContacts: \nIR@microbotmedical.com\nMedia@microbotmedical.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/346df7fb-c134-40c2-970a-39bcbaf974cd)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-16T12:30:00.670435866Z","server_sent_at_ms":1781613000670},"received_at":"2026-06-16T12:30:00.970Z","source_url":"https://www.globenewswire.com/news-release/2026/06/16/3312592/0/en/Microbot-Medical-Enters-Into-an-Agreement-to-Expand-Access-for-America-s-Veteran-and-Military-Patient-Populations.html"},"analysis":{"id":"54432","press_release_id":"65008","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Microbot Medical partnered with Lovell Government Services to distribute the LIBERTY Endovascular Robotic System to federal healthcare systems including the VA, Military Health System, and Indian Health Service.\n\nThe agreement places LIBERTY on Lovell’s Federal Supply Schedule contract with activation expected in Q3 2026, streamlining procurement for 170 federal medical centers.\n\nLovell Government Services, a Service-Disabled Veteran-Owned Small Business, serves thousands of government care sites averaging over 200 peripheral endovascular cases annually per site.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"GSA schedule listing opens federal channel for LIBERTY robot."},"keyFigures":{"customDimensions":{"medical_centers":170,"avg_annual_cases_per_site":"over 200"}},"quotedText":"We are proud to partner with Microbot Medical to help expand access to innovative healthcare technologies for our nation's veterans, active-duty service members, and Native American communities","namedEntities":{"people":[{"name":"Chris Lovell","role":"CEO of Lovell Government Services"},{"name":"Christina Bailey","role":"Vice President, U.S. Sales"}],"products":["LIBERTY Endovascular Robotic System"],"companies":[{"name":"Microbot Medical Inc.","ticker":"MBOT"},{"name":"Lovell Government Services","relationship":"distribution partner"},{"name":"Veterans Health Administration","relationship":"customer"},{"name":"Military Health System","relationship":"customer"},{"name":"U.S. Indian Health Service","relationship":"customer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Strategic distribution agreement to list the LIBERTY system on federal supply schedules expands addressable market to VA, DoD, and IHS, though no guaranteed revenue or purchase orders were announced."},"tickerRelevance":{"others":[],"primary":"MBOT"},"globalImportance":10,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"distribution-partnership","sectorWeight":"med-tech"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Microbot Medical partnered with Lovell Government Services to distribute the LIBERTY Endovascular Robotic System to federal healthcare systems including the VA, Military Health System, and Indian Health Service.\n\nThe agreement places LIBERTY on Lovell’s Federal Supply Schedule contract with activation expected in Q3 2026, streamlining procurement for 170 federal medical centers.\n\nLovell Government Services, a Service-Disabled Veteran-Owned Small Business, serves thousands of government care sites averaging over 200 peripheral endovascular cases annually per site.","key_figures":{"customDimensions":{"medical_centers":170,"avg_annual_cases_per_site":"over 200"}},"named_entities":{"people":[{"name":"Chris Lovell","role":"CEO of Lovell Government Services"},{"name":"Christina Bailey","role":"Vice President, U.S. Sales"}],"products":["LIBERTY Endovascular Robotic System"],"companies":[{"name":"Microbot Medical Inc.","ticker":"MBOT"},{"name":"Lovell Government Services","relationship":"distribution partner"},{"name":"Veterans Health Administration","relationship":"customer"},{"name":"Military Health System","relationship":"customer"},{"name":"U.S. Indian Health Service","relationship":"customer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-16T13:18:35.267Z","global_importance":10,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"distribution-partnership","sectorWeight":"med-tech"}},"durationMs":166739,"modelName":"george-droid-qwen-72b"}}